RxDoctor Payments Data

Angela Dolganiuc, MD

Gastroenterology · Beckley, WVNPI 1316232317

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 96.5% of the total across 63 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by AbbVie at 32.8% of the total. Reporting peaked in 2019 at $457 and has fallen 85.8% since, to $65 in 2025. That places this record below the midpoint for gastroenterology clinicians in WV, where the typical reported total is $1,371.

$1,196in general payments, 2019–2025

Across 63 payments — averaging $18.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$392
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$256
  • Pfizer$120
  • Takeda Pharmaceuticals U.S.A., Inc.$101
  • Boston Scientific$91
  • Bristol Myers Squibb$37
  • plus $199 from 10 others

What the payments were for

  • Food & beverage$1,15396%
  • Education$303%
  • Entertainment$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,196 in reported general payments places this provider in the 45th percentile of 72 gastroenterology providers in West Virginia.

See all gastroenterology providers in West Virginia

Medicare billing

Part B allowed, 2024
$162,589
Medicare patients
331
Services billed
1,530

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab32$288,143
XifaxanRifaximin42$159,729
LinzessLinaclotide89$103,108
CreonLipase/Protease/Amylase18$63,899
IbsrelaTenapanor Hcl20$44,867
Dexlansoprazole DrDexlansoprazole41$12,598
Sucralfate184$9,215
Famotidine592$8,516
SutabSod Sulf/Pot Chloride/Mag Sulf42$6,624
Colestipol Hcl38$5,052
Scopolamine26$4,863
Omeprazole282$4,537
Pantoprazole Sodium255$4,374
Rabeprazole Sodium29$3,815
Lactulose72$2,710

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon$392$167,007107 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$256$159,72942 claims
Braintree Laboratories, Inc.Sutab$18$6,62442 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 72 gastroenterology providers in West Virginia.

Other gastroenterology in Beckley

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →